Loading...
A Phase II Trial of The Oral Mtor Inhibitor Everolimus in Relapsed Hodgkin Lymphoma
PURPOSE: Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of rapamycin (mTORC1). The phosphatidylinositol 3-kinase/mTOR signal transduction pathway has been demonstrated to be activated in tumor samples from patients with Hodgkin Lymphoma (HL). The goal of this tri...
Na minha lista:
| Udgivet i: | Am J Hematol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4420736/ https://ncbi.nlm.nih.gov/pubmed/20229590 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21664 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|